Citations

Clear

1315 citation(s) found for "Kyle, RA".

Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies
Singleton, Kyle , Porter, Alyx B. , Hu, Leland , Johnston, Sandra K. , Bond, Kamila M. , Rickertsen, Cassandra , León, Gustavo De , Whitmire, Scott A., Clark-Swanson, Kamala , Mrugała, Maciej M. , Swanson, Kristin R. , Singleton, Kyle W , Rickertsen, Cassandra R, De Leon, Gustavo, Clark-Swanson, Kamala R., Swanson, Kristin R , Leon, Gustavo De

Mayo Clinic

Neuro-Oncology Advances | July 9, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaa085 | PMID 32864609 Get It

Abstract Background Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed to analyze days gained (DG), a burgeoning model-based dynamic metric, for response assessment in patients with recurrent GBM who received bevacizumab-based therapies. Methods DG response scores were calculated using volumetric tumor segmentations for patients receiving bevacizumab with and without concurrent cytotoxic therapy (N = 62). Kaplan–Meier and Cox proportional hazards analyses were implemented to examine DG prognostic relationship to overall (OS) and progression-free survival (PFS) from the onset of treatment for recurrent GBM. Results In patients receiving concurrent bevacizumab and cytotoxic therapy, Kaplan–Meier analysis showed significant differences in OS and PFS at DG cutoffs consistent with previously identified values from newly diagnosed GBM using T1-weighted gadolinium-enhanced magnetic resonance imaging (T1Gd). DG scores for bevacizumab monotherapy patients only approached significance for PFS. Cox regression showed that increases of 25 DG on T1Gd imaging were significantly associated with a 12.5% reduction in OS hazard for concurrent therapy patients and a 4.4% reduction in PFS hazard for bevacizumab monotherapy patients. Conclusion DG has significant meaning in recurrent therapy as a metric of treatment response, even in the context of anti-angiogenic therapies. This provides further evidence supporting the use of DG as an adjunct response metric that quantitatively connects treatment response and clinical outcomes.
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Reyes-Uribe, Laura , Wu, Wenhui , Gelincik, Ozkan , Bommi, Prashant V. , Solis, Luisa M., Lynch, Patrick M, Lim, Ramona M., Kanth, Priyanka , Samadder, N. Jewel , Mork, Maureen E. , Marnett, Lawrence J. , Vornik, Lana A. , Liu, Diane D. , Kopelovich, Levy, Wistuba, Ignacio I. , Lee, J Jack, Sei, Shizuko , Shoemaker, Robert H. , Szabó, Éva , Perloff, Marjorie , Lipkin, Steven M. , Lee, J. Jack , Kanth, Priyanka , Revuelta, Maria , Vilar, Eduardo , Szabo, Eva , Bommi, Prashant , Lee, J Jack , Francisco‐Cruz, Alejandro , Lynch, Patrick M, Stoffel, Elena M. , Taggart, Melissa W. , Milne, Ginger L. , Revuelta, María V. , Chang, Kyle , You, Y. Nancy , Lee, J Jack, Richmond, Ellen S. , Umar, Asad , Perloff, Marjorie, Brown, Powel H.

Mayo Clinic

Gut | July 8, 2020 | Volume: 70 | Issue: 3 | Pages: 555-566

10.1136/gutjnl-2020-320946 | PMID 32641470 Get It

Objective Patients with Lynch syndrome (LS) are at markedly increased risk for colorectal cancer. It is being increasingly recognised that the immune system plays an essential role in LS tumour development, thus making an ideal target for cancer prevention. Our objective was to evaluate the safety, assess the activity and discover novel molecular pathways involved in the activity of naproxen as primary and secondary chemoprevention in patients with LS. Design We conducted a Phase Ib, placebo-controlled, randomised clinical trial of two dose levels of naproxen sodium (440 and 220 mg) administered daily for 6 months to 80 participants with LS, and a co-clinical trial using a genetically engineered mouse model of LS and patient-derived organoids (PDOs). Results Overall, the total number of adverse events was not different across treatment arms with excellent tolerance of the intervention. The level of prostaglandin E2 in the colorectal mucosa was significantly decreased after treatment with naproxen when compared with placebo. Naproxen activated different resident immune cell types without any increase in lymphoid cellularity, and changed the expression patterns of the intestinal crypt towards epithelial differentiation and stem cell regulation. Naproxen demonstrated robust chemopreventive activity in a mouse co-clinical trial and gene expression profiles induced by naproxen in humans showed perfect discrimination of mice specimens with LS and PDOs treated with naproxen and control. Conclusions Naproxen is a promising strategy for immune interception in LS. We have discovered naproxen-induced gene expression profiles for their potential use as predictive biomarkers of drug activity. Trial registration number gov Identifier: NCT02052908
Patterns of oral anticoagulation use with cardioversion in clinical practice
Geurink, Kyle R. , Holmes, DaJuanicia N. , Ezekowitz, Michael D. , Pieper, Karen S. , Kowey, Peter R. , Reiffel, James A. , Singer, Daniel E. , Mahaffey, Kenneth W. , Piccini, Jonathan P. , Geurink, Kyle , Piccini, Jonathan P , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Pokorney, Sean D.

Mayo Clinic

Heart | June 26, 2020 | Volume: 107 | Issue: 8 | Pages: 642-649

10.1136/heartjnl-2019-316315 | PMID 32591363 Get It

Background Cardioversion is common among patients with atrial fibrillation (AF). We hypothesised that novel oral anticoagulants (NOAC) used in clinical practice resulted in similar rates of stroke compared with vitamin K antagonists (VKA) for cardioversion. Methods Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, patients with AF who had a cardioversion, follow-up data and an AF diagnosis within 6 months of enrolment were identified retrospectively. Clinical outcomes were compared for patients receiving a NOAC or VKA for 1 year following cardioversion. Results Among 13 004 patients with AF, 2260 (17%) underwent cardioversion. 1613 met the inclusion criteria for this analysis. At the time of cardioversion, 283 (17.5%) were receiving a VKA and 1330 (82.5%) a NOAC. A transoesophageal echocardiogram (TOE) was performed in 403 (25%) cardioversions. The incidence of stroke/transient ischaemic attack (TIA) at 30 days was the same for patients having (3.04 per 100 patient-years) or not having (3.04 per 100 patient-years) a TOE (p=0.99). There were no differences in the incidence of death (HR 1.19, 95% CI 0.62 to 2.28, p=0.61), cardiovascular hospitalisation (HR 1.02, 95% CI 0.76 to 1.35, p=0.91), stroke/TIA (HR 1.18, 95% CI 0.30 to 4.74, p=0.81) or bleeding-related hospitalisation (HR 1.29, 95% CI 0.66 to 2.52, p=0.45) at 1 year for patients treated with either a NOAC or VKA. Conclusions Cardioversion was a low-risk procedure for patients treated with NOAC, and there were statistically similar rates of stroke/TIA 30 days after cardioversion as for patients treated with VKA. There were no statically significant differences in death, stroke/TIA or major bleeding at 1 year among patients treated with NOAC compared with VKA after cardioversion.
Primary Alveolar Soft-Part Sarcoma of the Liver: Anomalous Presentation of a Rare Disease
Shaddix, Kyle K., Fakhre, G Peter, Nields, William W., Steers, Jeffery L., Hewitt, Winston R. , Menke, David M.

Mayo Clinic

The American Surgeon™ | June 17, 2020 | Volume: 74 | Issue: 1 | Pages: 43-46

10.1177/000313480807400109 Get It

Alveolar soft-part sarcoma is a highly vascular soft-tissue tumor that is uniformly malignant. It comprises less than 1 per cent of all soft-tissue sarcomas. Patients with alveolar soft-part sarcoma most frequently are aged 15 to 35 years, and the soft tissues of the lower extremities typically are affected. In the pediatric population, it most frequently occurs in the head and neck and particularly affects the tongue and orbit. Alveolar soft-part sarcoma has been described as a primary lesion in the trunk, upper extremities, and retroperitoneum; more novel locations include the mediastinum, female genital tract, stomach, bone, and larynx. Numerous case reports describe alveolar soft-part sarcoma in diverse anatomic locations, but this report is, to our knowledge, the first documentation of primary alveolar soft-part sarcoma of the liver. We describe a 47-year-old woman with such a manifestation. Despite surgical resection and numerous chemotherapeutic regimens, this patient had widespread metastasis and died approximately 2 years after the diagnosis was established.
High Patient Disease Burden in a Cross‐sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases
Jensen, Elizabeth T. , Aceves, Seema S. , Bonis, Peter A, Bray, Kimberly, Book, Wendy , Chehade, Mirna , Dellon, Evan S. , Gonsalves, Nirmala , Gupta, Sandeep K. , Hirano, Ikuo , Katzka, David A. , Kyle, Shay, Mack, Denise, Kodroff, Ellyn, Leung, John , Scott, Melissa, Paliana, Ally, Sable, Kathleen, Strobel, Mary Jo, Krischer, Jeffrey P. , group, CEGIR Investigator, Collins, Margaret H. , Falk, Gary W. , Mukkada, Vincent A. , Spergel, Jonathan M. , Rothenberg, Marc E. , Abonia, J. Pablo , group, CEGIR Investigator

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | June 15, 2020 | Volume: 71 | Issue: 4 | Pages: 524-529

10.1097/mpg.0000000000002817 | PMID 32541201 Get It

ABSTRACT Objectives: Clinical features of eosinophilic esophagitis (EoE) have been well‐described in the literature, however, characterization of features experienced by patients with other eosinophilic gastrointestinal diseases (EGIDs) is lacking. Using data collected from a patient contact registry, we sought to characterize and contrast patient‐reported gastrointestinal and extragastrointestinal symptoms and comorbidities in non‐EoE EGIDs, including eosinophilic gastritis, gastroenteritis and colitis, relative to EoE. Methods: We conducted a cross‐sectional study of contact registry data collected from 2015 to 2018. Statistical comparisons were made using chi‐square (categorical measures) and the Mann‐Whitney U test (continuous measures). Multivariable analyses were used to evaluate associations between treatment and feelings of isolation. Results: Of the 715 reporting an EGID diagnosis (n = 525 EoE; n = 190 non‐EoE EGID), a higher proportion of those with a non‐EoE EGID reported more frequent specific and nonspecific gastrointestinal symptoms, including nausea, abdominal pain, diarrhea, constipation, and bloating ( P < 0.01 for all). Participants with a non‐EoE EGID were more likely to report higher frequency of fatigue, isolation, and deep muscle or joint pain ( P < 0.01 for all). Specific food elimination and elemental formula treatments were associated with increased odds of more frequent (at least weekly) feelings of isolation for participants with EoE (adjusted odds rtaio [aOR]: 2.4; 95% confidence interval [CI]: 1.5‐‐4.1 for specific food elimination and adjusted OR: 1.9; 95% CI: 1.2‐‐3.3 for elemental formula). Conclusions: Significant differences exist in the symptoms and comorbidities experienced between those with EoE versus non‐EoE EGIDs. Additional investigation is needed to elucidate the factors that may contribute to the high disease burden of these poorly understood conditions.
Dynamic Three‐Dimensional Computed Tomography Mapping of Isometric Posterior Cruciate Ligament Attachment Sites on the Tibia and Femur: Single‐ Versus Double‐Bundle Analysis
Forsythe, Brian , Patel, Bhavik H. , Agarwalla, Avinesh , Puzzitiello, Richard N. , Verma, Nikhil N. , Cole, Brian J. , LaPrade, Robert F. , Inoue, Nozomu , LaPrade, Robert F , Forsythe, Brian , Lansdown, Drew Anderson , Kunze, Kyle N. , Lu, Yining , Chahla, Jorge

Mayo Clinic

Arthroscopy | June 15, 2020 | Volume: 36 | Issue: 11 | Pages: 2875-2884

10.1016/j.arthro.2020.06.006 | PMID 32554074 Get It

Purpose (1) To determine the area of posterior cruciate ligament (PCL) insertion sites on the lateral wall of the medial femoral condyle (LWMFC) that demonstrates the least amount of length change through full range of motion (ROM) and (2) to identify a range of flexion that would be favorable for graft tensioning for single‐bundle (SB) and double‐bundle (DB) PCL reconstruction. Methods Six fresh‐frozen cadaveric knees were obtained. Three‐dimensional computed tomography point‐cloud models were obtained from 0° to 135°. A point grid was placed on the LWMFC and the tibial PCL facet. Intra‐articular length was calculated for each point on the femur to the tibia at all flexion angles and grouped to represent areas for bone tunnels of SB and DB PCLR. Normalized length changes were evaluated. Results Femoral tunnel location and angle of graft fixation were significant contributors to mean, minimum, and maximum normalized length of the PCL (all p < .001). Tibial tunnel location was not significant in any case (all p < .22). A femoral tunnel in the location of the posteromedial bundle of the PCL resulted in the least length change at all tibial positions (maximum change 13%). Fixation of the anterolateral bundle in extension or at 30° flexion resulted in significant overconstraint of the PCL graft. The femoral tunnel location for a SB PCLR resulted in significant laxity at lower ranges of flexion. Conclusion PCL length was significantly dependent on femoral tunnel position and angle of fixation, whereas tibial tunnel position did not significantly contribute to observed differences. All PCL grafts demonstrated anisometry, with the anterolateral bundle being more anisometric than the posteromedial bundle. For DB PCLR, the posteromedial bundle demonstrated the highest degree of isometry throughout ROM, although no area of the LWMFC was truly isometric. The anterolateral bundle should be fixed at 90° to avoid overconstraint, and SB PCLR demonstrated significant laxity at lower ranges of flexion. Clinical Relevance Surgeons can apply the results of this investigation to surgical planning in PCLR to optimize isometry, which may ultimately reduce graft strain and the risk of graft failure. Additionally, DB PCLR demonstrated superiority compared with SB PCLR regarding graft isometry, as significant laxity was encountered at lower ranges of flexion in SB PCLRs. Fixation of the ALB at 90° flexion should be performed to avoid overconstraint in knee extension.
Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.
Abdallah, Nadine , Kapoor, Prashant , Lacy, Martha Q. , Hayman, Suzanne R. , Hobbs, Miriam, Kourelis, Taxiarchis , Kyle, Robert A. , Bergsagel, Leif P., Kumar, Shaji , Buadi, Francis K. , Greipp, Patricia T. , Gertz, Morie A. , Dispenzieri, Angela , Baughn, Linda B. , Dingli, David , Go, Ronald S. , Lin, Yi , Siddiqui, Mustaqeem , Ketterling, Rhett P. , Rajkumar, S. Vincent , Bergsagel, P. Leif

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e20520-e20520

10.1200/jco.2020.38.15_suppl.e20520 Get It

e20520 Background: Cytogenetic abnormalities detected by FISH are found in the majority of multiple myeloma (MM) patients. Although their prognostic value has been studied extensively, less is known about their association with disease characteristics and treatment response. Methods: To address these questions, we designed a retrospective study including 2031 Mayo Clinic patients diagnosed with MM from 2004 to 2018. We compared baseline characteristics and treatment outcomes between primary cytogenetic groups: t(11;14), t(4;14), t(14;16), (14;20), t(6;14), unknown IgH translocation/del and trisomy (without IgH translocation). These included 373, 177, 78, 20, 18, 228 and 791 patients respectively. Kruskal-Wallis and Fisher’s exact tests were used for categorical and continuous variables respectively. Time to next treatment (TTNT) was estimated using Kaplan-Meier method and compared using Log-Rank test. Results: t(4;14), t(14;16), t(6;14) and t(14;20) groups were associated with hemoglobin < 10 g/dL, beta2microglobulin > 5.5 µg/ml, ISS stage 3 and ≥50% bone marrow plasma cells. The latter 3 groups were also associated with renal dysfunction (Cr ≥2 mg/dL) and higher urinary monoclonal protein. t(4;14) was associated with IgA isotype, serum monoclonal protein ≥1g/dL and plasma cell labeling index ≥1%. Light chain myeloma was more prevalent in patients with t(11;14). Overall response rate (ORR) to proteasome inhibitor (PI) induction was higher for those with IgH translocations (any) compared to trisomies (85% vs 77% P = 0.02), while ORR was higher for those with trisomies with immunomodulatory drug (IMiD) induction (90% vs 78% P < 0.01). The rate of ≥ very good partial response was higher for patients with high risk IgH translocations [t(4;14), t(14;16) or t(14;20)] compared to standard risk with PI-IMiD combination treatment (88% vs 65% P < 0.01). Otherwise, response rates did not differ between these 2 groups. TTNT was longer in patients with trisomies compared to those with IgH translocation with IMiD or PI-IMiD treatments (32.2 vs 19 and 44 vs 27.4 months, respectively P < 0.01). For all cytogenetic groups, better treatment responses and longer TTNT were seen with PI-IMiD combinations compared to other treatments. Conclusions: t(4;14), t(14;16), t(6;14), and t(14;20) are associated with high risk disease characteristics. Patients with IgH translocations may have better response to PI induction compared to those with trisomies, while those with trisomies may have better response to IMiD treatment, with best outcomes for both seen with PI-IMiD combinations.
Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.
Nandakumar, Bharat , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Kourelis, Taxiarchis , Lust, John A., Warsame, Rahma , Hayman, Suzanne R. , Kyle, Robert A. , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Lin, Yi , Muchtar, Eli , Go, Ronald S. , Leung, Nelson , Jevremović, Dragan , Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson I.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e20510-e20510

10.1200/jco.2020.38.15_suppl.e20510 Get It

e20510 Background: pPCL is a rare and aggressive form of multiple myeloma (MM) with dismal survival outcomes compared to the remainder of MM patients. Several studies have validated the optimal cutoff for defining pPCL to be >5% circulating plasma cells (cPCs) on a peripheral blood smear due to equally poor outcomes in this less restrictive cohort. We evaluated the clinical outcomes and cytogenetic features of patients diagnosed with pPCL at our institution that were treated with novel agent induction therapies. Methods: We evaluated patients with pPCL diagnosed between 2000 – 2018 (using the 5% cut off) at Mayo Clinic, Minnesota. Data was extracted from a prospectively maintained database and from the review of electronic medical records. Patients were categorized as having high risk (HR) cytogenetics if any of the following abnormalities were present: del 17p, t(4;14), t(14;16) or t(14;20). Chi-square tests and Fisher exact tests were used to compare differences between sub-groups. Survival analysis was performed by the Kaplan-Meier method and differences assessed using the log rank test. Results: This cohort consisted of 67 patients with pPCL with a median age of 62 years (range: 34-91) of which 33 (46%) were male. The median follow up was 46 months (95% CI: 41 – 90). The median bone marrow plasma cell involvement was 84% (Range: 10 – 100) and the median cPCs percentage on the peripheral blood was 23% (range: 5 - 93). Data on primary cytogenetic abnormalities were available in 60 (85%) patients and the distribution was as follows: t(11;14) – 27 (45%), t(4;14) – 5 (8%), t(14;16) – 8 (13%), t(14;20)- 3(5%) and del 17p- 15(25%). All patients received novel agent induction therapy with 36 (54%) having received autologous stem cell transplant and 4 undergoing an allogeneic stem cell transplant. The median time to next therapy (TTNT) and overall survival (OS) for all patients was 13 months (95% CI: 9 – 17) and 24 months (95% CI: 19 – 40) respectively; 16 months and 51 months for standard risk (SR) vs. 10 months and 19 months for HR (P = 0.005 for OS), when stratified by cytogenetic risk. There were only 17 (31%) patients who were alive for ≥48 months since diagnosis (i.e. twice the median OS of this cohort); The absence of high risk cytogenetics (P = 0.049) and non-elevated LDH level (P = 0.047) at diagnosis predicted for achieving this survival goal. Conclusions: The outcomes of patients diagnosed with pPCL remain poor despite the use of novel agent induction therapy. However, some patients appear to do better than expected and this phenomenon may be influenced by the presence of HR cytogenetics.
Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia.
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Thompson, Carrie A. , King, Rebecca L. , He, Rong , Benanni, Nora N, Nowakowski, Grzegorz S. , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Gonsalves, Wilson I. , Muchtar, Eli

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 8550-8550

10.1200/jco.2020.38.15_suppl.8550 Get It

8550 Background: Waldenström Macroglobulinemia (WM) is a rare lymphoplasmacytic malignancy characterized by the presence of a recurrent point mutation in the MYD88 gene (MYD88L265P) in 80-95% of cases. Patients with MYD88WT genotype comprise a small subset that responds poorly to ibrutinib and other Bruton tyrosine kinase inhibitors. We examined the characteristics and outcome of WM patients with MYD88WT genotype predominantly treated with non-BTK inhibitor based therapies. Methods: Patients with a diagnosis of WM seen at Mayo Clinic, Rochester, between 1996 and 2018 were included. Their characteristics and outcomes were assessed from the time of active disease. Marrow MYD88 genotyping was assessed with an allele specific PCR assay (analytic sensitivity 1%). Categorical and continuous variables were compared using Chi square and Wilcoxon tests, respectively. Time-to-event analyses were performed using Kaplan Meier test. Results: Of 986 patients with active WM, MYD88 genotype data were available in 331 (34 %) patients; 72 (22%) and 260 (78%) patients harbored MYD88WT and MYD88L265P genotypes, respectively. The median follow-up was 5.8 years (95% CI: 5.0-6.5 years) from active WM; 6 years MYD88WT vs 5.4 years for MYD88L265P cohort. Median age was 63 years and 66 years in the MYD88WT and MYD88L265P cohorts, respectively (p = 0.07) with 46% and 53% patients being ≥65 years of age, respectively (p = 0.36). Pre-treatment marrow lymphoplasmacytic (LPL) infiltrate (median 40% for MYD88WT vs 60% for MYD88L265P; p = 0.001) and beta-2 microglobulin (median 3 µg/mL for MYD88WT vs 3.9 µg/mL for MYD88L265P; p = 0.02) were lower in the MYD88WT compared to the MYD88L265P cohort; other laboratory parameters at active disease were comparable. Per IPSSWM prognostic criteria, MYD88WT had fewer patients in the high risk group (18% for MYD88WT vs 42% MYD88L265P; p = 0.03). Patients with MYD88WT had higher likelihood of histological transformation [18% for MYD88WT vs 4% for MYD88L265P; odds ratio 5.8 (95% CI: 2.5-13.5; p < 0.0001)]. Among patients with treatment data available, only 35 (11%) patients received ibrutinib. The 5-year overall survival (OS) from active disease was comparable (85% in MYD88WT vs 82% in MYD88L265P cohort; p = 0.7). Conclusions: MYD88WT genotype in WM is associated with lower marrow LPL infiltration, lower likelihood of high-risk IPSSWM categorization and a higher likelihood of histological transformation in comparison to MYD88L265P mutant subpopulation. MYD88 genotype does not affect the OS from active disease in predominantly non-BTK inhibitor treated patients.
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma
Mellors, Patrick , Binder, Moritz , Greipp, Patricia T. , Peterson, Jess F. , Jevremović, Dragan , Pearce, Kathryn E., Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Kourelis, Taxiarchis , Warsame, Rahma , Lust, John A., Kyle, Robert A. , Kumar, Shaji , Mellors, Patrick W , Binder, Moritz , Peterson, Jess F , Jevremovic, Dragan , Greipp, Patricia T , Ketterling, Rhett P. , Baughn, Linda B. , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | May 22, 2020 | Volume: 4 | Issue: 10 | Pages: 2236-2244

10.1182/bloodadvances.2019001275 | PMID 32442300 Get It

AbstractMetaphase cytogenetic abnormalities, plasma cell proliferation index (PCPro), and gain 1q by fluorescence in situ hybridization (FISH) are associated with inferior survival in newly diagnosed multiple myeloma (MM) treated with novel agents; however, their role in risk stratification is unclear in the era of the revised International Staging System (R-ISS). The objective of this study was to determine if these predictors improve risk stratification in newly diagnosed MM when accounting for R-ISS and age. We studied a retrospective cohort of 483 patients with newly diagnosed MM treated with proteasome inhibitors and/or immunomodulators. On multivariable analysis, R-ISS, age, metaphase cytogenetic abnormalities (both in aggregate and for specific abnormalities), PCPro, and FISH gain 1q were associated with inferior progression-free (PFS) and overall survival (OS). We devised a risk scoring system based on hazard ratios from multivariable analyses and assigned patients to low-, intermediate-, and high-risk groups based on their cumulative scores. The addition of metaphase cytogenetic abnormalities, PCPro, and FISH gain 1q to a risk scoring system accounting for R-ISS and age did not improve risk discrimination of Kaplan-Meier estimates for PFS or OS. Moreover, they did not improve prognostic performance when evaluated by Uno’s censoring-adjusted C-statistic. Lastly, we performed a paired analysis of metaphase cytogenetic and interphase FISH abnormalities, which revealed the former to be insensitive for the detection of prognostic chromosomal abnormalities. Ultimately, metaphase cytogenetics lack sensitivity for important chromosomal aberrations and, along with PCPro and FISH gain 1q, do not improve risk stratification in MM when accounting for R-ISS and age.